BARC Asia​

Brand Advertising Research & Consulting Pvt. Ltd. (BARC) is a research-based consultancy leveraging an array of services to global brands with expertise in crafting branding solutions and analysis of brand equity, marketing campaigns, market research, product development and content marketing, with a blend of innovation for growth in various industries.

Sino Biopharmaceutical Limited, together with its subsidiaries, is a leading, innovative and research and development driven pharmaceutical conglomerate in the People's Republic of China encompassing a fully integrated chain in pharmaceutical products.

The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for treating tumours, liver disease, cardio-cerebral diseases, analgesia, respiratory system diseases and orthopaedic diseases. 


In order to enhance their sustainable competitiveness, they attach great importance to R&D breakthroughs and is positioned as an industry leader in terms of R&D expenditures and product innovation.

In May 2018, a new chemical Category 1 drug of antitumor – Focus V (Anlotinib Hydrochloride) capsule obtained the approval for drug registration granted by State Food and Drug Administration of the PRC.


The medicines which have received Good Manufacturing Practice (“GMP”) certifications issued by the State Food and Drug Administration of the PRC and for health food in capsules from the Department of Health of Jiangsu Province.


The Group also actively establishes and extends co-operations with leading domestic and overseas pharmaceutical institutes and enterprises, with a view to bringing about the ecological commercialization of world-frontier R&D results to benefit the mankind. CTTQ Pharmaceutical Group features low-carbon mechanism in all processes of pharmaceutical production.

• The Group actively utilizes new technologies in Big Data, Artificial Intelligence and Financial Technology to continuously enhance the efficiency of the management, R&D, manufacturing and sales activities.


• The Company was included in Forbes Asia's “Asia Fab 50 Companies” for three consecutive years in 2016, 2017 and 2018.

• Their subsidiary research center of CT Tianqing is also named as the only ‘New Hepatitis Medicine Research Center’ in the country.